phase readout
saveNCT06563895: Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
RECRUITINGupdated 2mo ago
community read0 votes
Sponsor: Eidos Therapeutics, a BridgeBio company. Phase: PHASE3. Conditions: Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies, Heart Diseases, Polyneuropathies
view source ↗
comments(0)
5-min edit window · permanent after that